Sign in Subscribe

Archive

A collection of 715 issues

Latest

AI-assisted colonoscopy cost-effectiveness study evaluates financial impact in Singapore

Skip to content The CRC Digest ▪ SCREENING AI-assisted colonoscopy cost-effectiveness study evaluates financial impact in Singapore Computer-assisted detection (CADe) during screening colonoscopy improves adenoma detection rates while reducing endoscopists' mental fatigue. (Int J Surg) This content is informational only and does not constitute medical advice. Always consult your oncologist

Case series from Tanzania documents colorectal cancer in patients under 30

Skip to content The CRC Digest ♥ LIVING WITH CRC Case series from Tanzania documents colorectal cancer in patients under 30 Three patients under age 30 presented with advanced disease after prolonged symptoms including rectal bleeding and weight loss; two had mucinous adenocarcinoma and one had a family history suggesting hereditary

Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer While approved KRAS therapies target only the rare G12C mutation, new drugs including MRTX1133, zoldonrasib, and daraxonrasib are being developed to directly target G12D and G12V—the most common

First Colombian report of MUTYH-associated polyposis with novel mutations

Skip to content The CRC Digest ◇ RESEARCH First Colombian report of MUTYH-associated polyposis with novel mutations Case series from Colombia's Tolima Grande region describes individuals carrying pathogenic MUTYH variants c.452A>G and c.1353_1355del associated with polyposis phenotypes and colorectal cancer predisposition. (Frontiers in Oncology)

CRISPR-Cas9 electroporation targets KRAS G12V mutation in CRC cells

Skip to content The CRC Digest ◇ RESEARCH CRISPR-Cas9 electroporation targets KRAS G12V mutation in CRC cells Researchers used direct electroporation of Cas9 ribonucleoproteins to achieve allele-specific disruption of KRAS p.G12V in SW480 colorectal cancer cells, assessing delivery efficiency and on-target editing. (Iranian Journal of Basic Medical Sciences) This content

Bispecific antibody co-targeting EGFR and CDH17 reduces skin toxicity in preclinical CRC models

Skip to content The CRC Digest ◇ RESEARCH Bispecific antibody co-targeting EGFR and CDH17 reduces skin toxicity in preclinical CRC models A bispecific antibody co-targeting EGFR and cadherin-17 (CDH17) achieved superior tumor growth inhibition compared to EGFR- or c-MET/EGFR-targeting antibodies while reducing skin-related toxicities in preclinical colorectal cancer studies. The

Mutant allele frequency in ctDNA may guide EGFR rechallenge decisions in metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH Mutant allele frequency in ctDNA may guide EGFR rechallenge decisions in metastatic CRC Research published in JCO Precision Oncology explores how relative mutant allele frequency in circulating tumor DNA (ctDNA) could help determine when to rechallenge patients with anti-EGFR therapy after resistance develops.

Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC This multicenter, randomized phase 3 trial evaluated first-line anlotinib versus bevacizumab plus CapeOX in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer. (Nature via Google

CRC Research Update — September 01, 2026

Today's colorectal cancer research highlights

PET/CT metabolic parameters predict microsatellite instability status in colorectal cancer

Skip to content The CRC Digest PET/CT metabolic parameters predict microsatellite instability status in colorectal cancer Researchers developed a non-invasive nomogram model using preoperative 18F-FDG PET/CT metabolic parameters to predict MSI status in 156 CRC patients, potentially guiding personalized treatment decisions. (Rev Esp Med Nucl Imagen Mol) This